As drug makers face an increasingly competitive landscape and development costs continue to rise, biopharmaceutical firms big and small are seeking every advantage to maximize the value of their R&D efforts. As a result, many companies have flocked to Asia-Pacific for better access to patients, lower costs, and operational efficiencies.

Beyond meeting the needs of global pharma in simply providing access to patient pools and lower operational costs, the region is also poised to realize the potential of a thriving biotechnology sector that is driving innovation on its own. From China to India, Singapore to Malaysia, to Sri Lanka and beyond, Asia is gaining the experience and infrastructure needed to support the global biotech industry by performing work and fostering innovation that moves higher and higher up the pharmaceutical value chain.

To read the full, original article click on this link: Asia-Pacific’s March toward a New Drug Development Paradigm

Author: Ferzaan Engineer, Ph.D. and Anand Tharmaratnam, M.D.